English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

P .  vivax  and  P .  falciparum  parasites display different tropism for host cells and induce very different clinical symptoms and pathology, suggesting that the immune responses required for protection may differ between these two species. However, no study has qualitatively compared the immune responses to  P .  falciparum  or  P .  vivax  in humans following primary exposure and infection. Here, we show that the two species differ in terms of the cellular immune responses elicited following primary infection. Specifically,  P .  vivax  induced the expansion of a subset of CD8 +  T cells expressing the activation marker CD38, whereas  P .  falciparum  induced the expansion of CD38 +  CD4 +  T cells. The CD38 +  CD8 +  T cell population that expanded following  P .  vivax  infection displayed greater cytotoxic potential compared to CD38 -  CD8 +  T cells, and compared to CD38 +  CD8 +  T cells circulating during  P .  falciparum  infection. We hypothesize that  P .  vivax  infection leads to a stronger CD38 +  CD8 +  T cell activation because of its preferred tropism for MHC-I-expressing reticulocytes that, unlike mature red blood cells, can present antigen directly to CD8 +  T cells. This study provides the first line of evidence to suggest an effector role for CD8 +  T cells in  P .  vivax  blood-stage immunity. It is also the first report of species-specific differences in the subset of T cells that are expanded following primary  Plasmodium  infection, suggesting that malaria vaccine development may require optimization according to the target parasite.   Trial Registration  anzctr.org.au  ACTRN12612000814875 ; anzctr.org.au  ACTRN12613000565741 ; anzctr.org.au  ACTRN12613001040752 ; ClinicalTrials.gov  NCT02281344 ; anzctr.org.au  ACTRN12612001096842 ; anzctr.org.au  ACTRN12613001008718

plos neglected tropical diseases

Plasmodium vivax but Not Plasmodium falciparum Blood-Stage Infection in Humans Is Associated with the Expansion of a CD8+ T Cell Population with Cytotoxic Potential